Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Nature|July 24, 2024
Human TMEFF1 is a restriction factor for herpes simplex virus in the brainYi-Hao Chan, Zhiyong Liu, Paul Bastard, et al.
The Journal of Experimental Medicine|June 16, 2022
Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumoniaQian Zhang, Daniela Matuozzo, Jérémie Le Pen, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCsMonique G P van der Wijst, Sara E Vazquez, George C Hartoularos, et al.
Science Immunology|May 26, 2021
Polyclonal expansion of TCR Vbeta 21.3<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells is a hallmark of Multisystem Inflammatory Syndrome in ChildrenMarion Moreews, Kenz Le Gouge, Samira Khaldi-Plassart, et al.
Science Translational Medicine|August 25, 2021
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19Monique G P van der Wijst, Sara E Vazquez, George C Hartoularos, et al.
The Journal of Experimental Medicine|February 5, 2021
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccinePaul Bastard, Eleftherios Michailidis, Hans-Heinrich Hoffmann, et al.
The Journal of Experimental Medicine|November 7, 2022
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccinationAurélien Sokal, Paul Bastard, Pascal Chappert, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
Journal of Human Immunity|March 16, 2026
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
BMC Infectious Diseases|June 27, 2022
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical studyManuel Rojas, Yhojan Rodríguez, Juan Carlos Hernández, et al.
Pageof 13